Update on diagnostic and treatment of uncomplicated and complicated malaria in adults and selected vulnerable populations

Philip Botha, Emmanuel Bottieau, Olalekan Uthman, Ude Obike, Jean B. Nachega

Research output: Contribution to journalArticle

Abstract

Although malaria remains one of the most important infectious causes of morbidity and mortality world-wide with 40% of the global population at risk, significant progress has been made toward elimination, notably with the development and use of rapid diagnostic tests, insecticide-treated bed nets, indoor residual spraying, and artemisinin-based combination therapies (ACTs). P. falciparum infection remains the most common cause of severe infection and death, but non-P. P. falciparum infections, including the recently emerged 5th plasmodium species, P. knowlesi, are increasingly recognized as causes of severe disease, especially in southeast Asia. Chemotherapy for severe infections has been revolutionized following results of the SEQUAMAT and AQUAMAT trials showing that parenteral artesunate (versus quinine) reduced severe malaria mortality by 34.7% and 22.5% in Asian adults and African children, respectively, making it the drug of choice for severe malaria. However, rising rates of artemisinin resistance, currently confined to the Greater Mekong sub-region, are threatening the long-term efficacy of artemisinins. HIV infection remains an important risk factor for death and severe disease due to malaria. The full amplitude of mutual interactions between these conditions is only beginning to be elucidated while the complex, multi-directional and pharmacokinetic interactions between antimalarial agents and HIV drugs continue to emerge.

Original languageEnglish (US)
Pages (from-to)278-291
Number of pages14
JournalInfectious Disorders - Drug Targets
Volume13
Issue number4
DOIs
StatePublished - 2013

Fingerprint

Vulnerable Populations
Malaria
Infection
Artemisinins
Insecticide-Treated Bednets
Southeastern Asia
Quinine
Plasmodium
Mortality
Antimalarials
Therapeutics
Routine Diagnostic Tests
Pharmaceutical Preparations
HIV Infections
Pharmacokinetics
HIV
Morbidity
Drug Therapy
artemisinine

Keywords

  • Artemisinin
  • Malaria
  • Quinine
  • Treatment

ASJC Scopus subject areas

  • Molecular Medicine
  • Microbiology (medical)
  • Pharmacology

Cite this

Update on diagnostic and treatment of uncomplicated and complicated malaria in adults and selected vulnerable populations. / Botha, Philip; Bottieau, Emmanuel; Uthman, Olalekan; Obike, Ude; Nachega, Jean B.

In: Infectious Disorders - Drug Targets, Vol. 13, No. 4, 2013, p. 278-291.

Research output: Contribution to journalArticle

Botha, Philip ; Bottieau, Emmanuel ; Uthman, Olalekan ; Obike, Ude ; Nachega, Jean B. / Update on diagnostic and treatment of uncomplicated and complicated malaria in adults and selected vulnerable populations. In: Infectious Disorders - Drug Targets. 2013 ; Vol. 13, No. 4. pp. 278-291.
@article{d5a4ef896d5a44a7b604818aad243be3,
title = "Update on diagnostic and treatment of uncomplicated and complicated malaria in adults and selected vulnerable populations",
abstract = "Although malaria remains one of the most important infectious causes of morbidity and mortality world-wide with 40{\%} of the global population at risk, significant progress has been made toward elimination, notably with the development and use of rapid diagnostic tests, insecticide-treated bed nets, indoor residual spraying, and artemisinin-based combination therapies (ACTs). P. falciparum infection remains the most common cause of severe infection and death, but non-P. P. falciparum infections, including the recently emerged 5th plasmodium species, P. knowlesi, are increasingly recognized as causes of severe disease, especially in southeast Asia. Chemotherapy for severe infections has been revolutionized following results of the SEQUAMAT and AQUAMAT trials showing that parenteral artesunate (versus quinine) reduced severe malaria mortality by 34.7{\%} and 22.5{\%} in Asian adults and African children, respectively, making it the drug of choice for severe malaria. However, rising rates of artemisinin resistance, currently confined to the Greater Mekong sub-region, are threatening the long-term efficacy of artemisinins. HIV infection remains an important risk factor for death and severe disease due to malaria. The full amplitude of mutual interactions between these conditions is only beginning to be elucidated while the complex, multi-directional and pharmacokinetic interactions between antimalarial agents and HIV drugs continue to emerge.",
keywords = "Artemisinin, Malaria, Quinine, Treatment",
author = "Philip Botha and Emmanuel Bottieau and Olalekan Uthman and Ude Obike and Nachega, {Jean B.}",
year = "2013",
doi = "10.2174/1871526513666140103122630",
language = "English (US)",
volume = "13",
pages = "278--291",
journal = "Infectious Disorders - Drug Targets",
issn = "1871-5265",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Update on diagnostic and treatment of uncomplicated and complicated malaria in adults and selected vulnerable populations

AU - Botha, Philip

AU - Bottieau, Emmanuel

AU - Uthman, Olalekan

AU - Obike, Ude

AU - Nachega, Jean B.

PY - 2013

Y1 - 2013

N2 - Although malaria remains one of the most important infectious causes of morbidity and mortality world-wide with 40% of the global population at risk, significant progress has been made toward elimination, notably with the development and use of rapid diagnostic tests, insecticide-treated bed nets, indoor residual spraying, and artemisinin-based combination therapies (ACTs). P. falciparum infection remains the most common cause of severe infection and death, but non-P. P. falciparum infections, including the recently emerged 5th plasmodium species, P. knowlesi, are increasingly recognized as causes of severe disease, especially in southeast Asia. Chemotherapy for severe infections has been revolutionized following results of the SEQUAMAT and AQUAMAT trials showing that parenteral artesunate (versus quinine) reduced severe malaria mortality by 34.7% and 22.5% in Asian adults and African children, respectively, making it the drug of choice for severe malaria. However, rising rates of artemisinin resistance, currently confined to the Greater Mekong sub-region, are threatening the long-term efficacy of artemisinins. HIV infection remains an important risk factor for death and severe disease due to malaria. The full amplitude of mutual interactions between these conditions is only beginning to be elucidated while the complex, multi-directional and pharmacokinetic interactions between antimalarial agents and HIV drugs continue to emerge.

AB - Although malaria remains one of the most important infectious causes of morbidity and mortality world-wide with 40% of the global population at risk, significant progress has been made toward elimination, notably with the development and use of rapid diagnostic tests, insecticide-treated bed nets, indoor residual spraying, and artemisinin-based combination therapies (ACTs). P. falciparum infection remains the most common cause of severe infection and death, but non-P. P. falciparum infections, including the recently emerged 5th plasmodium species, P. knowlesi, are increasingly recognized as causes of severe disease, especially in southeast Asia. Chemotherapy for severe infections has been revolutionized following results of the SEQUAMAT and AQUAMAT trials showing that parenteral artesunate (versus quinine) reduced severe malaria mortality by 34.7% and 22.5% in Asian adults and African children, respectively, making it the drug of choice for severe malaria. However, rising rates of artemisinin resistance, currently confined to the Greater Mekong sub-region, are threatening the long-term efficacy of artemisinins. HIV infection remains an important risk factor for death and severe disease due to malaria. The full amplitude of mutual interactions between these conditions is only beginning to be elucidated while the complex, multi-directional and pharmacokinetic interactions between antimalarial agents and HIV drugs continue to emerge.

KW - Artemisinin

KW - Malaria

KW - Quinine

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84893439234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893439234&partnerID=8YFLogxK

U2 - 10.2174/1871526513666140103122630

DO - 10.2174/1871526513666140103122630

M3 - Article

C2 - 24387665

AN - SCOPUS:84893439234

VL - 13

SP - 278

EP - 291

JO - Infectious Disorders - Drug Targets

JF - Infectious Disorders - Drug Targets

SN - 1871-5265

IS - 4

ER -